Motilal Oswal: Aurobindo Pharma’s Natrol Divestment - Review
A person inspects a sample of pills. (Photographer: Antoine Antoniol/Bloomberg)

Motilal Oswal: Aurobindo Pharma’s Natrol Divestment - Review

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Motilal Oswal Report

Aurobindo Pharma Ltd. has announced the divestment of Natrol, a wholly owned unit of its U.S.-based subsidiary, for 550 million U.S. dollar (approximately Rs 40 billion) as an all-cash deal.

Considering Natrol’s FY20 sales/profit after tax at 157 million U.S. dollar /27 million U.S. dollar, the deal is attractive at valuation of 3.5 times enterprise value/sales and 20 times price/earning on FY20 basis.

The company is expected to use the funds to further reduce its debt and strengthen future product pipeline.

Click on the attachment to read the full report:

Motilal Oswal Aurobinod Pharma Company Update.pdf

DISCLAIMER

This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.